论文部分内容阅读
目的:研究布拉酵母菌预防新生儿感染性肺炎继发腹泻的临床疗效及对免疫功能的影响,探究其临床适用性。方法:选择从2012年2月至2014年11月于宁波市妇女儿童医院接受治疗的140例感染性肺炎新生儿作为研究病例,简单随机分为研究组和对照组两组,两组患者在常规抗生素治疗的同时,对照组患儿在出现腹泻时予蒙脱石治疗,试验组患儿常规治疗肺炎同时加口服布拉菌预防。观察两组患者继发性腹泻情况;并比较两组患者治疗前后T细胞亚群计数、临床疗效及不良反应发生率。结果:治疗过程中对照组患儿出现继发腹泻32例,占45.71%,研究组患儿出现腹泻9例,占12.86%,两组患儿继发性腹泻发生率比较,差异有统计学意义(χ2=18.2459,P=0.0000)。研究组患者的腹泻总时间、腹泻持续时间、腹泻出现时间、治疗72h后腹泻次数均显著优于对照组,两组比较,差异均具有统计学意义(P<0.05);治疗前,研究组患者的CD4+、CD8+、CD4+/CD8+与对照组患者的水平含量基本相符,两组比较,差异均无统计学意义(P>0.05);治疗后,研究组患者的CD4+、CD8+、CD4+/CD8+水平含量均显著优于对照组,两组比较,差异均具有统计学意义(P<0.05);用药过程中,两组患者的不良反应发生率均很低,差异具有统计学意义(P>0.05)。结论:布拉酵母菌可以显著地预防新生儿感染性肺炎继发腹泻,预后效果良好,不良反应少,安全可靠,适合临床长期推广应用。
Objective: To study the clinical efficacy and the immune function of Saccharomyces boulardii in preventing secondary diarrhea in neonates with infectious pneumonia and explore its clinical applicability. Methods: From January 2012 to November 2014, 140 infants with infectious pneumonia admitted to Ningbo Women and Children’s Hospital were selected as study cases and randomly divided into study group and control group. The two groups were treated in routine Antibiotic treatment at the same time, the control group of children in the event of diarrhea to montmorillonite treatment, the experimental group of children with conventional treatment of pneumonia plus oral Bola by the prevention. The incidence of secondary diarrhea in both groups was observed. The counts of T cells, clinical efficacy and incidence of adverse reactions in both groups before and after treatment were compared. Results: In the control group, 32 cases of secondary diarrhea occurred in the control group (45.71%), and 9 cases (12.86%) of the children in the study group had diarrhea. The incidence of secondary diarrhea in both groups was statistically significant (χ2 = 18.2459, P = 0.0000). The total duration of diarrhea, the duration of diarrhea, the time of diarrhea and the number of diarrhea after 72 hours of treatment in study group were significantly better than those in control group. There was significant difference between the two groups (P <0.05). Before treatment, patients in study group The levels of CD4 +, CD8 +, CD4 + / CD8 + in the study group were basically the same as those in the control group. There was no significant difference between the two groups (P> 0.05) Were significantly better than the control group, the two groups were compared, the differences were statistically significant (P <0.05); medication during the two groups of patients with adverse reactions were very low incidence rate, the difference was statistically significant (P> 0.05). Conclusion: Saccharomyces boulardii can significantly prevent secondary diarrhea caused by infectious pneumonia in neonates with good prognosis, less adverse reactions, safe and reliable, and is suitable for long-term clinical application.